

Dietary conjugated linoleic acid (CLA) induces apoptosis of colonic mucosa in 1,2-dimethylhydrazine-treated rats: a possible mechanism of the anticarcinogenic effect by CLA

Hyun S. Park¹, Ji H. Ryu¹, Yeong L. Ha² and Jung H. Y. Park^{3*}

¹Department of Food and Nutrition, Kyung Hee University, Seoul, Korea

²Department of Agricultural Chemistry, Gyeongsang National University, Chinju, Korea

³Division of Life Sciences and Institute of Environment & Life Science, Hallym University, Chunchon, Korea

(Received 15 March 2001 – Revised 21 June 2001 – Accepted 17 July 2001)

One of the objectives of the present study was to investigate whether 1% conjugated linoleic acid (CLA) in the diet reduced tumour incidence in the colon of 1,2-dimethylhydrazine (DMH)-treated rats. Colon cancer was induced by injecting 6-week-old, male, Sprague–Dawley rats with 15 mg/kg DMH twice per week for 6 weeks. They were fed either 1% CLA or a control diet *ad libitum* for 30 weeks. Dietary CLA significantly decreased colon tumour incidence ($P < 0.05$). Our second objective was to investigate whether apoptosis in the colon mucosa of DMH-treated rats was affected by the amount of dietary CLA and whether the changes in apoptosis were related to those in fatty acid-responsive biomarkers. For this purpose, rats were killed after being fed a diet containing 0%, 0.5%, 1% or 1.5% CLA for 14 weeks. CLA was undetected in the mucosa of rats fed the 0% CLA diet and increased to 5.9 mg/g phospholipid in rats fed the 0.5% diet. The apoptotic index estimated by the terminal deoxynucleotidyl transferase-mediated dUTP nick and labelling technique was increased by 251% and the 1,2-diacylglycerol content was decreased by 57% in rats fed 0.5% CLA. No further changes in these variables were observed when CLA in the diet was raised to 1.0% or 1.5%. However, dietary CLA decreased mucosal levels of prostaglandin E₂, thromboxane B₂ and arachidonic acid in a dose-dependent manner. The present data indicate that dietary CLA can inhibit DMH-induced colon carcinogenesis by mechanisms probably involving increased apoptosis.

Conjugated linoleic acid: Colon cancer: Prostaglandin E₂: Thromboxane B₂: 1,2-diacylglycerol: Apoptosis

Conjugated linoleic acid (CLA) is found in natural sources, such as the fat of milk and meat of ruminant animals. CLA is a collective term used to denote one or more positional and geometric isomers of linoleic acid (*cis*-9,*cis*-12-18:2). In animal studies, CLA has proved to be a potent anticarcinogen (Parodi, 1997) reducing the incidence of chemically induced epidermal, mammary and forestomach tumours in mice and aberrant crypt foci in the rat colon. Since colon cancer is one of the most frequent malignant diseases in the Western world, it is important to study the mechanisms by which dietary CLA inhibits colon carcinogenesis.

Increased expression of cyclo-oxygenase (COX) and overproduction of prostaglandins (PG) have been indicated in the development and progression of colorectal cancer.

Colon cancer is prevented or attenuated in mice or humans treated with COX inhibitors (Oshima *et al.* 1996; Williams *et al.* 1997; Prescott & Fitzpatrick, 2000). As CLA and linoleic acid are likely to share the same enzyme system for chain elongation and desaturation, CLA feeding decreases the amount of linoleic acid metabolites including 18:3n-6, 20:3n-6 and 20:4n-6 in mammary tissues (Banni *et al.* 1999). Decreased arachidonate, a substrate for COX and lipoxygenase, would result in decreased eicosanoid synthesis. Indeed, PGE₂ and 6-keto-PGF_{1α} levels have been reported to be reduced in the colon mucosa of CLA-fed rats (Xu & Dashwood, 1999). *In vitro* studies have also shown that CLA inhibits PGE₂ synthesis from arachidonate in murine keratinocytes (Liu & Belury, 1998). The eicosanoid receptors have been shown to control the release

Abbreviations: CLA, conjugated linoleic acid; COX, cyclo-oxygenase; DAG, 1,2-diacylglycerol; DMH, 1,2-dimethylhydrazine; NSAID, non-steroidal anti-inflammatory drugs; PG, prostaglandin; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling; TX, thromboxane.

* **Corresponding author:** Professor Jung H. Y. Park, fax +82 33 256 0199, email jyoong@sun.hallym.ac.kr

of second messengers such as cyclic AMP, 1,2-diacylglycerol (DAG) and inositol-1,4,5-trisphosphate, which are important for cell proliferation, differentiation and apoptosis (Marks *et al.* 2000). Overexpression of COX-2 inhibits apoptosis (Tsuji & DuBois, 1995) and apoptosis appears to mediate the chemopreventive effects of non-steroidal anti-inflammatory drugs (NSAID; Samaha *et al.* 1997). Therefore, it can be hypothesized that dietary CLA inhibits colon carcinogenesis by inducing apoptosis through mechanisms involving inhibition of eicosanoid synthesis.

The present study investigated whether dietary CLA inhibited colon tumorigenesis induced by 1,2-dimethylhydrazine (DMH) in rats. In addition, we investigated whether CLA stimulated apoptosis in the colon mucosa and whether the changes in apoptosis stimulated by CLA were related to other fatty acid-responsive biomarkers such as PGE₂, thromboxane (TX)B₂ and DAG.

Methods

Experiment 1

All experimental procedures were conducted in compliance with the revised National Institutes of Health Guide for the Care and Use of Laboratory Animals. Sixty male Sprague–Dawley rats, 6 weeks of age, were purchased from Deahan Animal Experimental Center (Choong-buk, Korea). Upon arrival, they were individually housed in hanging stainless-steel cages on a 12 : 12 h light–dark cycle and given Purina rat chow (Ralston-Purina, St Louis, MO, USA) and tap water *ad libitum*. After 7 d of acclimatization, all rats were injected intramuscularly with DMH (Aldrich Chemical Co., Milwaukee, WI, USA) at a dose of 15 mg/kg body weight twice per week for 6 weeks to deliver a total dose of 180 mg/kg. At the same time, the rats were randomly divided into two dietary groups and fed either the control or the experimental diet *ad libitum*. The composition of the control diet was as follows (g/kg): maize starch, 565; casein, 220; L-methionine, 3; cellulose, 40; beef tallow, 96.4; maize oil, 23.6; American Institute of Nutrition (AIN): AIN-76 mineral mix, 40; modified AIN-76 vitamin mix, 10; choline bitartrate, 2. The experimental diet contained the same dietary ingredients as the control diet, except that this diet contained 12.5 g CLA-rich oil in place of a portion of the beef tallow. CLA-rich oil was synthesized from commercial safflower oil by alkali isomerization as previously described (Kim *et al.* 2000) and the fatty acid profile of the oil was determined by GC as described further. The CLA-rich oil contained 80% CLA isomers, and the isomeric composition of the CLA was 50.7% *trans*-10,*cis*-12, 47.2% *cis*-9,*trans*-11 CLA, 1.2% *trans*, *trans*-CLA and 0.9% other CLA isomers. The fatty acid composition of diets is shown in Table 1. The amount of CLA-rich oil was calculated to formulate a diet containing 1% (w/w) pure CLA. Food intakes and body weights were determined weekly. The animals were killed 30 weeks after the initiation of feeding of the experimental diets, and the colon was removed, opened, washed in PBS, fixed in 10% buffered formalin and examined under a dissecting microscope for neoplasm.

Table 1. The fatty acid composition of diets used in experiment 1

Fatty acid	0.0% CLA (g/100 g diet)	1.0% CLA (g/100 g diet)
C14:0	0.30	0.26
C14:1	0.11	0.12
C16:0	2.53	2.24
C16:1	0.39	0.34
C17:1	0.10	0.08
C18:0	1.77	1.56
C18:1	4.70	4.31
C18:2 <i>n</i> -6	1.69	1.74
C18:3 <i>n</i> -3	0.02	0.02
CLA*	0.00	1.00
C20:0	0.11	0.10
Unknown	0.22	0.22
Total	11.94	11.99

CLA, conjugated linoleic acid.

*The isomeric composition of the CLA was 50.7% *trans*-10,*cis*-12, 47.2% *cis*-9,*trans*-11 CLA, 1.2% *trans*, *trans*-CLA and 0.9% other CLA isomers.

Experiment 2

Animals, diet and study protocols. After acclimatization, rats received intramuscular injections of DMH as described earlier. Immediately before the initiation of the DMH injections, the animals were randomly divided into four groups and fed a diet containing 0%, 0.5%, 1%, or 1.5% (w/w) CLA *ad libitum* (Table 2). They were killed 14 weeks after the initiation of the DMH injections and feeding of experimental diets. The colon was removed and 1 cm segments of the distal colon were rinsed in PBS and fixed in 10% buffered formalin for the estimation of apoptotic cells. The remaining mucosa was scraped from the underlying tissue with a glass slide for the determination of PGE₂, TXB₂, DAG and fatty acid composition of phospholipids.

Determination of fatty acid profile of phospholipids and 1,2-diacylglycerol levels in the colonic mucosa. Mucosal lipids were extracted according to Bligh & Dyer (1959) and phospholipids were isolated by TLC by the method of Duncan *et al.* (1993). Fatty acid methyl esters were prepared (Lepage & Roy, 1984) and fatty acid compositions were analysed by GC using a Hewlett-Packard 5890 II series chromatograph equipped with flame-ionization detector (Hewlett-Packard, Downers Grove, IL, USA) and a fused silica capillary column (SP-2330, 0.25 mm ID × 60 m; Supelco, Bellefonte, PA, USA). The initial and final temperatures were 170°C and 245°C respectively, with a temperature programme 2°C rise/min after a 4 min delay at 170°C. For the determination of mucosal levels of DAG, total lipids were extracted from the mucosa as described earlier. DAG was separated on a silica gel TLC plate according to the method described by Duncan *et al.* (1993), scraped from the plate, and quantified as described by Fletcher (1968) using DAG as a standard.

Apoptosis. The fixed tissues were embedded in paraffin, and paraffin sections (4 μm thickness) were mounted on albumin-coated glass slides and deparaffinized. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) was carried out utilizing an *in situ* cell death detection kit (AP; Roche Molecular Biochemical, Mannheim, Germany) according to Gavrieli *et al.* (1992).

Table 2. Composition of the diets used in experiment 2 (g/100 g). Percentages are of pure conjugated linoleic acid (CLA) in the diet

	0% CLA	0.5% CLA	1.0% CLA	1.5% CLA
Maize starch	54.60	54.60	54.60	54.60
Casein	21.60	21.60	21.60	21.60
L-methionine	0.30	0.30	0.30	0.30
Cellulose	3.70	3.70	3.70	3.70
Fat sources				
Beef tallow	12.0	11.23	10.47	9.70
Maize oil*	2.50	2.55	2.59	2.63
CLA-rich oil†	—	0.72	1.44	2.15
AIN-76 mineral mix	4.00	4.00	4.00	4.00
AIN-76 vitamin mix	1.00	1.00	1.00	1.00
Choline bitartrate	0.30	0.30	0.30	0.30

* The amount of maize oil was added to supply 1.79% linoleic acid in each diet.

† CLA-rich oil contained 70% CLA isomers, and the isomeric composition of the CLA was 56% *trans*-10,*cis*-12 and 39% *cis*-9,*trans*-11-CLA.

Samples were counterstained with methyl green prior to analysis by light microscopy. Ten vertically oriented crypt and villus columns were evaluated per animal. The numbers of apoptotic cells and total cells were counted. The apoptotic index was calculated as the number of nuclei divided by the total number of nuclei per crypt column.

Determination of prostaglandin E_2 and thromboxane B_2 levels. Mucosa was homogenized in 0.05 M-Tris buffer, pH 8.0, containing 0.25 M-sucrose and 1 mM EDTA and centrifuged at 4000 g for 15 min, and the supernatant was saved as described previously (Vanderhoof *et al.* 1988). PGE₂ and TXB₂ were extracted by a solid-phase C-18 cartridge (Alltech Associates, Inc., Deerfield, IL, USA), and the amounts of PGE₂ and TXB₂ were determined using the enzyme immunoassay kits according to the manufacturer's instructions (Cayman, Ann Arbor, MI, USA).

Statistical analysis. Data were analysed using the Statistical Analysis Systems statistical software package version 6.12 (SAS Institute, Cary, NC, USA). Tumour incidences at the final time point were compared by χ^2 test and the total tumour yield between the control and the CLA-treated groups was compared by frequency distribution analysis. Most data were expressed as means and standard deviations. One-way ANOVA, followed by Duncan's multiple range test, was used to analyse the data from experiment 2. The level of significance was set at $P < 0.05$.

Results

Experiment 1

To examine whether feeding a diet containing 1% CLA reduced the incidence of colon tumours, tumours were induced in rats by injecting DMH at the dose of 15 mg/kg twice per week for 6 weeks. Feeding rats with the diet containing 1% CLA had no effect on the pattern of food intake or weight gain during the 30 weeks of the experimental period compared to the pattern in control rats (data not shown). As shown in Table 3, the incidence of tumours was significantly lower in rats fed the 1% CLA diet compared to control rats ($P < 0.05$).

Experiment 2

Since we observed that the diet containing 1% CLA significantly reduced the incidence of tumours, the following experiments were performed to examine the mechanisms by which CLA inhibited colon carcinogenesis. The rats were injected with DMH as in experiment 1, but were fed diets containing different levels of CLA (0%, 0.5%, 1%, or 1.5%) for 14 weeks. In this part of the study, examination of the colonic mucosa was carried out before the development of grossly visible neoplasia. There were no differences in growth characteristics and food intake patterns of rats during the 14 week period among the four dietary groups (data not shown).

The rate of tumour growth is dependent upon a balance between the rates of cell proliferation and apoptosis. To determine whether apoptotic rates of colonic mucosal cells were increased by dietary CLA, apoptosis was estimated *in situ* by the TUNEL technique. As shown in Table 4, the apoptotic index was significantly increased in rats fed the 0.5% CLA diet compared to control rats fed no CLA ($P < 0.05$). However, there was no significant difference in the apoptotic index among the three groups fed different levels of CLA.

To examine whether changes in apoptosis observed in CLA-fed rats were related to mucosal PG and TX levels, PGE₂ and TXB₂ were quantified by enzyme immunoassays. Dietary CLA decreased levels of PGE₂ and TXB₂ in the colonic mucosa in a dose-dependent manner. However, neither the difference in these parameters between the 0.5%

Table 3. Effects of conjugated linoleic acid (CLA) on 1,2-dimethylhydrazine (DMH)-induced colon tumours in rats. Autopsy was performed after feeding DMH-treated rats with the indicated diet for 30 weeks

Diet	Tumour incidence†	Total tumour number	Mean tumour number per rat
Control	12/30	18	0.60
CLA	7/30*	10*	0.33*

† Number of tumour-bearing rats/total number of rats in each group. Significantly different from control: * $P < 0.05$.

Table 4. Effect of conjugated linoleic acid (CLA) on apoptotic index in the colonic mucosa of rats treated with 1,2-dimethylhydrazine (Mean values and standard deviations)

Dietary group (% CLA)	Number of rats	Apoptotic index	
		Mean	SD
0.0	5	0.1985 ^b	0.0664
0.5	6	0.4983 ^a	0.1961
1.0	5	0.4577 ^a	0.1486
1.5	5	0.5159 ^a	0.0492

^{a,b} Values with unlike superscript letters were significantly different ($P < 0.05$).

Table 5. Effect of conjugated linoleic acid (CLA) on mucosal prostaglandin (PG)E₂ and thromboxane (TX)B₂ levels (ng/mg tissue) in the colon of rats treated with 1,2-dimethylhydrazine (Mean values and standard deviations)

Dietary group (% CLA)	Number of rats	PGE ₂		TXB ₂	
		Mean	SD	Mean	SD
0	7	21.06 ^a	1.11	6.91 ^a	1.11
0.5	9	16.04 ^b	4.19	5.70 ^b	1.01
1.0	7	14.14 ^{bc}	2.80	4.41 ^{bc}	0.81
1.5	8	10.47 ^c	5.28	3.78 ^c	0.56

^{a,b,c} Values with unlike superscript letters were significantly different ($P < 0.05$).

Table 6. Effect of conjugated linoleic acid (CLA) on the fatty acid composition of mucosal phospholipids of the colon in rats treated with 1,2-dimethylhydrazine

(Mean and standard deviations for values expressed as milligrams fatty acid per gram phospholipid)

Dietary group (% CLA)	Number of rats	CLA		AA	
		Mean	SD	Mean	SD
0	6	ND	—	5.13 ^a	2.02
0.5	6	5.88 ^a	5.60	3.65 ^{ab}	1.27
1.0	6	7.68 ^a	6.58	1.66 ^b	1.91
1.5	6	6.04 ^a	3.07	1.80 ^b	1.70

AA, arachidonic acid; ND, not detected.

^{a,b} Values with unlike superscript letters were significantly different ($P < 0.05$).

Table 7. Effect of conjugated linoleic acid (CLA) on 1,2-diacylglycerol (DAG) levels of the colonic mucosa in rats treated with 1,2-dimethylhydrazine

(Mean and standard deviations for values expressed as nanograms per milligram tissue)

Dietary group (% CLA)	Number of rats	DAG	
		Mean	SD
0	6	0.23 ^a	0.12
0.5	6	0.10 ^b	0.04
1.0	8	0.14 ^b	0.06
1.5	8	0.12 ^b	0.04

^{a,b} Values with unlike superscript letters were significantly different ($P < 0.05$).

and 1.0% CLA groups nor the difference between the 1.0% and 1.5% groups was statistically significant (Table 5).

To examine whether the decreased PGE₂ and TXB₂ levels were related to fatty acid profiles of cell membranes, the mucosal phospholipids were separated. As shown in Table 6, CLA was not detectable when rats were fed the 0% CLA diet. When rats were fed the diet containing 0.5% CLA, the levels of CLA reached 5.88 mg/g mucosal phospholipids. However, increases in dietary CLA over 0.5% did not further increase CLA content of mucosal phospholipids in the colon of DMH-injected rats. By contrast, arachidonic acid content decreased significantly in the 1.0% and 1.5% CLA groups compared to the 0.0% CLA group ($P < 0.05$). CLA feeding did not alter the proportion of any other fatty acid (data not shown).

Another possible means by which CLA could increase apoptosis in the colonic mucosa would be to decrease DAG levels in mucosal cells. Mucosal DAG levels were significantly lower in the 0.5% CLA group than those in the 0% CLA group ($P < 0.05$). However, there were no differences in DAG levels among the groups fed different levels of CLA (Table 7).

Discussion

The present study has clearly shown that dietary CLA at 1% concentration inhibits DMH-induced colon carcinogenesis in rats. It has been reported that CLA administered by gavage at a level of 0.5% of diet (w/w) reduced formation of heterocyclic amine-induced aberrant foci in the colon of Fisher 344 rats (Liew *et al.* 1995; Xu & Dashwood, 1999). In addition to colon cancers, studies with rat mammary cancers induced by 7,12-dimethylbenz[α]anthracene (Ip *et al.* 1996) showed that the inhibitory effect of CLA reached a maximum at 1% regardless of the levels of fat in the diet. In studies with transplantable murine mammary tumours grown in mice fed 20% fat diets, Hubbard *et al.* (2000) observed that the concentration of CLA required for inhibition of mammary tumour metastasis was as little as 0.1% of the diet compared with diets containing no CLA. It was also reported that CLA decreased local growth and the metastatic properties of the DU-145 human prostate carcinoma cell line in mice suffering from severe combined immunodeficiency (Cesano *et al.* 1998). Mice receiving a diet supplemented with 1% CLA not only displayed smaller local tumours than mice receiving the regular diet but also had a drastic reduction in lung metastases. Results of all these studies indicate that concentrations of CLA $\leq 1%$ are sufficient for producing significant cancer protection in rodent models.

The anti-carcinogenic effect of CLA shown in the present study may be isomer specific. However, the synthetically prepared CLA used in the present study contained eight different isomers, with two particular isomers, *trans*-10, *cis*-12 and *cis*-9, *trans*-11, accounting for about 97% of the total. We have *in vitro* data indicating that CLA inhibits proliferation of the human colon cancer cell line Caco-2, which is owing to the effect of the *trans*-10, *cis*-12 isomer (Kim *et al.* 2001). It remains to be determined whether this isomer is the biologically active species for colon cancer prevention *in vivo*.

Cancer is frequently described as a disorder of the balance between cell proliferation and cell death. We observed that dietary CLA increased the apoptotic index in the colon mucosa, indicating that CLA inhibits DMH-induced colon carcinogenesis by inducing apoptosis. Recently, Ip *et al.* (2000) reported that CLA induced apoptosis and reduced the expression of bcl-2 in premalignant lesions of the rat mammary gland but not in normal mammary gland. However, we cannot rule out the possibility that CLA induces proliferation arrest of mucosal cells, as the present experiments did not determine whether inhibition of colon cancer by CLA was due to decreased cellular proliferation. *In vitro* studies have shown that CLA inhibits the proliferation of MCF-7 human breast cancer cells. Cell cycle analysis indicated that more of the MCF-7 cells remained in the G₀/G₁ cycle when the cells were cultured with CLA (Durgam & Fernandes, 1997).

Phosphatidylinositol-4,5-bisphosphate is part of a second messenger system that transduces signals of many hormones. The membrane-bound phospholipase C catalyses the hydrolysis of phosphatidylinositol-4,5-bisphosphate at its glycerol-phospho bond, yielding inositol-1,4,5-trisphosphate and DAG. The non-polar DAG product of phospholipase C action is a lipid-soluble second messenger remaining in the plasma membrane, where it activates protein kinase C to phosphorylate and thereby modulate the activities of several cellular proteins. Protein kinase C has been proposed to play an important role in the aetiology of colon cancer by regulating gene expression and a variety of cellular functions, including proliferation, differentiation, tumorigenesis and apoptosis (Nishizuka, 1986, 1988; Newton, 1997). It has been reported that DAG was down-regulated during apoptotic cell death (Voziyan *et al.* 1995; Chen *et al.* 2000) and exogenous DAG inhibited the apoptosis triggered by farnesol, ceramide and daunorubicin (Jarvis *et al.* 1994a; Voziyan *et al.* 1995; Mansat *et al.* 1997), suggesting DAG as an important antiapoptotic and survival signal. In the present study, changes in DAG levels (Table 7) were negatively related to those in the apoptotic index in the colon mucosa of CLA-fed rats (Table 4). These results are consistent with the hypothesis that DAG is a positive intracellular mitogenic agent (Jarvis *et al.* 1994b; Flores *et al.* 2000).

Previous studies using both genetic and pharmacological approaches have established that COX-2 plays a role in the development of colorectal cancer (Gupta & DuBois, 1998; Williams *et al.* 1999). NSAID such as sulindac cause regression of precancerous colonic lesions in animals (Moorghen *et al.* 1988) and human subjects (Takayama *et al.* 1998). NSAID exert their chemopreventive effects by inhibiting COX-2-dependent (Prescott & White, 1996) or COX-2-independent pathways that trigger apoptosis (Piazza *et al.* 1995; Shiff *et al.* 1995). In the present study, CLA lowered both PGE₂ and TXB₂ levels in a dose-dependent manner in the colonic mucosa of DMH-injected rats (Table 5). These results are consistent with the results of Xu & Dashwood (1999) showing that PGE₂ and 6-keto-PGF_{1α} were reduced in the colonic mucosa of CLA-fed rats. Similar decreases in PGE₂ synthesis by CLA were observed in the epidermis of mice treated topically with the tumour promoter 12-*O*-tetradecanoylphorbol-13-acetate

(Kavanaugh *et al.* 1999). Since CLA reduced PGE₂ and TXB₂, a tenable hypothesis is that CLA and NSAID share a common path of action in promoting the apoptotic process.

Dietary CLA reduced the arachidonate content of phospholipids in the colonic mucosa of DMH-treated rats (Table 6). These decreases in arachidonate may have caused the decreased PGE₂ and TXB₂ observed in these animals. Using *in vitro* mouse keratinocyte cultures, Liu & Belury (1998) observed that CLA decreased cellular AA content and arachidonate-derived PGE₂ synthesis induced by 12-*O*-tetradecanoylphorbol-13-acetate. Sébédio *et al.* (1997) have shown that rats fed a fat-free diet for 2 weeks metabolized a CLA mixture to C20:3Δ^{8,12,14}, C20:4Δ^{5,8,12,14}, and C20:4Δ^{5,8,11,13} with a higher quantity of C20:4Δ^{5,8,12,14} than C20:4Δ^{5,8,11,13}. C20:4Δ^{5,8,12,14} and C20:4Δ^{5,8,11,13} must arise from the elongation and desaturation of 18:2Δ^{10,12} and 18:2Δ^{9,11} respectively. As the present study did not measure these products, we can only speculate that CLA was desaturated and elongated to the 20 C conjugated fatty acids that decreased arachidonate-derived PGE₂ and TXB₂ in the colonic mucosa of our CLA-fed animals. Mechanisms by which dietary CLA modulates arachidonic acid metabolism needs to be investigated further.

In summary, dietary CLA reduced the incidence of tumours, and induced apoptosis in the colonic mucosa of DMH-treated rats, suggesting that CLA inhibits colon carcinogenesis, at least in part, by increasing apoptosis. Levels of regulators of cell responses, PGE₂, TXB₂ and DAG, decreased in the colonic mucosa of CLA-fed rats. These results suggest that the increased apoptosis by dietary CLA may be, at least in part, attributable to changes in arachidonic acid metabolism in CLA-fed rats. The precise signalling event involved in CLA-induced apoptosis in colon mucosal cells remains to be determined further.

Acknowledgements

The present study was supported by a grant from KOSEF (no. 1999-2-220-004-5). The authors thank Dr Carolanne Nelson for her critical review of this manuscript.

References

- Banni S, Angioni E, Casu V, Melis MP, Carta G, Corongiu FP, Thompson H & Ip C (1999) Decrease in linoleic acid metabolites as a potential mechanism in cancer risk reduction by conjugated linoleic acid. *Carcinogenesis* **20**, 1019–1024.
- Bligh E & Dyer W (1959) A rapid method of total lipid extraction and purification. *Canadian Journal of Biochemistry and Physiology* **37**, 911–917.
- Cesano A, Visonneau S, Scimeca JA, Kritchevsky D & Santoli D (1998) Opposite effects of linoleic acid and conjugated linoleic acid on human prostatic cancer in SCID mice. *Anticancer Research* **18**, 1429–1434.
- Chen J, Chai M, Chen H, Zhao S & Song J (2000) Regulation of phospholipase D activity and ceramide production in daunorubicin-induced apoptosis in A-431 cells. *Biochimica et Biophysica Acta* **1488**, 219–232.

- Duncan EM, Tunbridge LJ & Lloyd JV (1993) An increase in phosphatidic acid in the absence of changes in diacylglycerol in human platelets stimulated with ADP. *International Journal of Biochemistry* **25**, 23–27.
- Durgam VR & Fernandes G (1997) The growth inhibitory effect of conjugated linoleic acid on MCF-7 cells is related to estrogen response system. *Cancer Letters* **116**, 121–130.
- Fletcher MJ (1968) A colorimetric method for estimating serum triglycerides. *Clinica Chimica Acta* **22**, 393–397.
- Flores I, Jones DR & Merida I (2000) Changes in the balance between mitogenic and antimitogenic lipid second messengers during proliferation, cell arrest, and apoptosis in T-lymphocytes. *FASEB Journal* **14**, 1873–1875.
- Gavrieli Y, Sherman Y & Ben-Sasson SA (1992) Identification of programmed cell death *in situ* via specific labeling of nuclear DNA fragmentation. *Journal of Cell Biology* **119**, 493–501.
- Gupta RA & DuBois RN (1998) Aspirin, NSAIDs, and colon cancer prevention: mechanisms? [editorial]. *Gastroenterology* **114**, 1095–1098.
- Hubbard NE, Lim D, Summers L & Erickson KL (2000) Reduction of murine mammary tumor metastasis by conjugated linoleic acid. *Cancer Letters* **150**, 93–100.
- Ip C, Briggs SP, Haeghele AD, Thompson HJ, Storkson J & Scimeca JA (1996) The efficacy of conjugated linoleic acid in mammary cancer prevention is independent of the level or type of fat in the diet. *Carcinogenesis* **17**, 1045–1050.
- Ip C, Ip M, Luftus T, Shoemaker S & Shea-Eaton W (2000) Induction of apoptosis by conjugated linoleic acid in cultured mammary tumor cells and premalignant lesions of the rat mammary gland. *Cancer Epidemiology Biomarkers Prevention* **9**, 689–696.
- Jarvis WD, Fornari FA Jr, Browning JL, Gewirtz DA, Kolesnick RN & Grant S (1994a) Attenuation of ceramide-induced apoptosis by diglyceride in human myeloid leukemia cells. *Journal of Biological Chemistry* **269**, 31685–31692.
- Jarvis WD, Povirk LF, Turner AJ, Traylor RS, Gewirtz DA, Pettit GR & Grant S (1994b) Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. *Biochemical Pharmacology* **47**, 839–852.
- Kavanaugh CJ, Liu KL & Belury MA (1999) Effect of dietary conjugated linoleic acid on phorbol ester-induced PGE2 production and hyperplasia in mouse epidermis. *Nutrition and Cancer* **33**, 132–138.
- Kim EJ, Cho HJ, Ha YL & Park JHY (2001) The *trans*-10, *cis*-12 isomer of conjugated linoleic acids (CLA) inhibits proliferation of the human colon cancer cell line Caco-2. *FASEB Journal* **15**, A283.
- Kim Y, Lee Y, Park K, Kim J & Ha Y (2000) A simple method for the preparation of highly pure conjugated linoleic acid (CLA) synthesized from safflower oil. *Journal of Food Sciences and Nutrition* **5**, 10–14.
- Lepage G & Roy CC (1984) Improved recovery of fatty acid through direct transesterification without prior extraction or purification. *Journal of Lipid Research* **25**, 1391–1396.
- Liew C, Schut HA, Chin SF, Pariza MW & Dashwood RH (1995) Protection of conjugated linoleic acids against 2-amino-3-methylimidazo[4,5-f]quinoline-induced colon carcinogenesis in the F344 rat: a study of inhibitory mechanisms. *Carcinogenesis* **16**, 3037–3043.
- Liu KL & Belury MA (1998) Conjugated linoleic acid reduces arachidonic acid content and PGE2 synthesis in murine keratinocytes. *Cancer Letters* **127**, 15–22.
- Mansat V, Laurent G, Levade T, Bettaieb A & Jaffrezou JP (1997) The protein kinase C activators phorbol esters and phosphatidylserine inhibit neutral sphingomyelinase activation, ceramide generation, and apoptosis triggered by daunorubicin. *Cancer Research* **57**, 5300–5304.
- Marks F, Muller-Decker K & Furstenberger G (2000) A causal relationship between unscheduled eicosanoid signaling and tumor development: cancer chemoprevention by inhibitors of arachidonic acid metabolism. *Toxicology* **153**, 11–26.
- Moorghen M, Ince P, Finney KJ, Sunter JP, Appleton DR & Watson AJ (1988) A protective effect of sulindac against chemically-induced primary colonic tumours in mice. *Journal of Pathology* **156**, 341–347.
- Newton AC (1997) Regulation of protein kinase C. *Current Opinion in Cell Biology* **9**, 161–167.
- Nishizuka Y (1986) Perspectives on the role of protein kinase C in stimulus–response coupling. *Journal of National Cancer Institute* **76**, 363–370.
- Nishizuka Y (1988) The molecular heterogeneity of protein kinase C and its implications for cellular regulation. *Nature* **334**, 661–665.
- Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF & Taketo MM (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). *Cell* **87**, 803–809.
- Parodi PW (1997) Cows' milk fat components as potential anticarcinogenic agents. *Journal of Nutrition* **127**, 1055–1060.
- Piazza GA, Rahm AL, Krutzsch M, Sperl G, Paranka NS, Gross PH, Brendel K, Burt RW, Alberts DS & Pamukcu R (1995) Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. *Cancer Research* **55**, 3110–3116.
- Prescott SM & Fitzpatrick FA (2000) Cyclooxygenase-2 and carcinogenesis. *Biochimica et Biophysica Acta* **1470**, M69–M78.
- Prescott SM & White RL (1996) Self-promotion? Intimate connections between APC and prostaglandin H synthase-2. *Cell* **87**, 783–786.
- Samaha H, Kelloff G, Steele V, Rao C & Reddy B (1997) Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as biomarker in colon cancer chemoprevention and promotion. *Cancer Research* **57**, 1301–1305.
- Sébédio JL, Juaneda P, Dobson G, Ramilison I, Martin JC, Chardigny JM & Christie WW (1997) Metabolites of conjugated isomers of linoleic acid (CLA) in the rat. *Biochimica et Biophysica Acta* **1345**, 5–10.
- Shiff SJ, Qiao L, Tsai LL & Rigas B (1995) Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. *Journal of Clinical Investigation* **96**, 491–503.
- Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, Kato J, Kogawa K, Miyake H & Niitsu Y (1998) Aberrant crypt foci of the colon as precursors of adenoma and cancer. *New England Journal of Medicine* **339**, 1277–1284.
- Tsuji M & DuBois R (1995) Alteration in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. *Cell* **83**, 493–501.
- Vanderhoof J, Park J & Grandjean C (1988) Reduced mucosal prostaglandin synthesis after massive small bowel resection. *American Journal of Physiology* **254**, G373–G377.
- Voziyan PA, Haug JS & Melnykovich G (1995) Mechanism of farnesol cytotoxicity: further evidence for the role of

- PKC-dependent signal transduction in farnesol-induced apoptotic cell death. *Biochemical and Biophysical Research Communications* **212**, 479–486.
- Williams CS, Mann M & DuBois RN (1999) The role of cyclooxygenases in inflammation, cancer, and development. *Oncogene* **18**, 7908–7916.
- Williams CS, Smalley W & DuBois RN (1997) Aspirin use and potential mechanisms for colorectal cancer prevention. *Journal of Clinical Investigation* **100**, 1325–1329.
- Xu M & Dashwood RH (1999) Chemoprevention studies of heterocyclic amine-induced colon carcinogenesis. *Cancer Letters* **143**, 179–183.